Certara, Inc. (CERT)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 4
Do Nothing: qualitativeScore is 2 (below required floor of 3); strategy requires qualitativeScore >= 3 before any bullish entry - the upstream qualitative screen flagged the abrupt CFO departure and determinate-negative sentiment, and no chart pattern overrides that.
Company overview
Certara, Inc. provides biosimulation software and services for drug development, from discovery to market entry. Its offerings include mechanistic and empirical biosimulation, regulatory support, and market access consultation. The company serves biopharmaceutical firms, academic institutions, and government organizations globally.
Fundamental
fairCertara shows solid revenue growth and margins but faces profitability and interest coverage challenges.
Score 3 (Mixed): revenue has grown ~10% CAGR with strong gross/EBITDA margins and positive free cash flow, but recent SEC filings show operating losses, a divestiture-related discontinued-ops hit, and weak interest coverage. Liquidity looks sufficient (cash ~$184M, $100M revolver available, no covenant issues disclosed), yet valuation is around fair value (EV/EBITDA ~16.5x; DCF slightly below price), limiting upside until profitability re-accelerates.
Sentiment
weakSentiment is negative due to earnings misses, leadership changes, and lack of engagement.
Dominant catalyst is the bearish Q2 2026 earnings print (announced, 2026-08-04): revenue rose only 1% and results lagged estimates while the net loss widened and shares fell ~16%, with no offsetting bullish catalyst in-window; media sentiment is negative (aggregate polarity_score ≈ −0.12) and the delta is determinate-negative (baseline dominated by the Q1 miss, the ~−19% slide, target trims and the CFO exit), with a moderate red-flag cap applied for the abrupt CFO departure without an identified successor.
Technical
goodThe stock is in a recovering uptrend, trading above key moving averages with positive momentum.
Score 4 (strong setup, one weak signal): price above a fully-aligned bullish moving-average stack (SMA20 8.20, SMA50 7.51, SMA200 7.22, EMA9 8.24, EMA21 8.10), MACD line positive above zero at 0.21, and healthy ~$21.3M 20-day dollar volume; the single weak signal is cooling momentum (MACD histogram -0.06, ADX14 13.3) during the two-week consolidation below the 8.89 swing high.
You’re looking at 2026-09-02 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.